Robert D. Inman

Reduction of CXCR3 + CCR6 + CD4 + T Cells and IL ‐17+ RORγt + CD4 + T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy

OBJECTIVE: We recently reported an immune profile that stratifies patients with axial spondyloarthritis based on clinical response to secukinumab. We now undertake an exploratory study on the secukinumab nonresponder patients to determine if immunologic changes occur during their...